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Abstract
Diabetic retinopathy (DR) affects approximately one-third of diabetic patients and, if left 
untreated, progresses to proliferative DR (PDR) with associated vitreous hemorrhage, retinal 
detachment, iris neovascularization, glaucoma and irreversible blindness. In vitreous samples of 
human patients with PDR, we found elevated levels of hypoxia inducible factor 1 alpha (HIF1α). 
HIFs are transcription factors that promote hypoxia adaptation and have important functional roles 
in a wide range of ischemic and inflammatory diseases. To recreate the human PDR phenotype for 
a preclinical animal model, we generated a mouse with neuroretinal-specific loss of the von Hippel 
Lindau tumor suppressor protein, a protein that targets HIF1α for ubiquitination. We found that 
the neuroretinal cells in these mice overexpressed HIF1α and developed severe, irreversible 
ischemic retinopathy that has features of human PDR. Rapid progression of retinopathy in these 
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mutant mice should facilitate the evaluation of therapeutic agents for ischemic and inflammatory 
blinding disorders. In addition, this model system can be used to manipulate the modulation of the 
hypoxia signaling pathways, for the treatment of non-ocular ischemic and inflammatory disorders.
INTRODUCTION
Diabetes is the leading cause of blindness among the working-age population,1 with 
approximately one-third of diabetic patients displaying signs of diabetic retinopathy (DR).2,3 
Clinically, DR is classified into two progressive stages. The first stage is non-proliferative 
DR, characterized by intraretinal microvascular abnormalities, microaneurysms and hard 
exudates. Within 10 years, ~ 60% of non-proliferative DR patients progress to the second 
stage, proliferative DR (PDR),2,4 during which capillary dropout renders the retina ischemic. 
If left untreated, patients with PDR can develop retinal neovascularization (angiogenesis), 
vitreous hemorrhage, intraocular fibrosis, tractional retinal detachment, retinal degeneration, 
neovascular glaucoma and eventual blindness.2,5
Cadavers are currently the only source of human retinal neurons affected by PDR, so a 
murine model neuroretinal hypoxic signaling in a new preclinical murine model for 
proliferative diabetic retinopathy would be a powerful tool for testing the progressive 
clinical phenotype, neovascularization and ischemia. Most available mouse models of DR 
are inadequate, because within the lifespan of the diabetic animals, they develop only a mild, 
non-proliferative disease.6,7 For example, although the O2-induced retinopathy and Kimba/
Akimba vascular endothelial growth factor (VEGF) transgenic mouse models have been 
useful for studying retinopathy of prematurity and vascular leakage, in these mice, 
neovascularization spontaneously regresses and so limits testing of many therapeutic 
hypotheses.2,8–13 Although the newest murine model for DR (a Per2 mutant) displays gene 
expression patterns similar to DR human patients, the mice do not develop the vascular 
abnormalities characteristic of human PDR.14
To develop an appropriate murine model for human PDR, we characterized protein profiles 
in human vitreous samples, comparing DR patients and control subjects. Our goal was to 
find a pathway that, when dysregulated, causes retinal hypoxia and leaky neovascularization, 
key pathologic symptoms of PDR. We determined that hypoxia inducible factors (HIFs) are 
highly elevated in PDR patient vitreous samples. HIFs are αβ-heterodimeric transcription 
factors that have a key role in the regulation of tissue metabolism, stress and the adaptation 
to hypoxic conditions.15 HIFs have gained interest in pharmacological studies for their role 
in a wide range of ischemic and inflammatory diseases, such as renal anemia, inflammatory 
bowel disease, wound healing and many others. At adequate tissue oxygen levels, HIFs are 
rapidly degraded via the E3 ubiquitin ligase proteasomal pathway by interaction with the 
von Hippel Lindau tumor suppressor protein (VHL). Therefore, we created a conditional 
knockout of VHL in the neuroretina of mice, and found that the photoreceptor cells released 
elevated levels of HIF1α that led to a severe, progressive, neovascular, PDR phenotype in 
the mouse, creating a model for the understanding of HIF signaling pathways and the testing 
of therapeutic agents for the treatment of PDR and other ischemic diseases.
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MATERIALS AND METHODS
Human cases
The collection of data used in this study was approved by the Institutional Review Board for 
Human Subjects Research at the University of Iowa, was compliant with the Health 
Insurance Portability and Accountability Act, and adhered to the tenets of the Declaration of 
Helsinki. Written informed consent was received from participants before inclusion in the 
study. Clinical examination and testing were performed as previously described.16 
Stereoscopic color fundus images and infrared images were obtained using a Topcon TRC 
50DX camera (Topcon, Paramus, NJ, USA).
Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay was performed using the human/mouse total HIF-1 
alpha DuoSet IC (DYC1935; R&D Systems, Inc., Minneapolis, MN, USA).
Mouse lines and husbandry
All animal studies were conducted in accordance with the Association for Research in 
Vision and Ophthalmology Statement for Use of Animals in Ophthalmic and Vision 
Research as well as the Policy for the Use of Animals in Neuroscience Research of the 
Society for Neuroscience, and procedures were approved by the Institutional Animal Care 
and Use Committee of Columbia University. All mice were housed in the Columbia 
University Pathogen-free Eye IC and maintained in temperature-controlled rooms with a 
12/12-h light/dark cycle. The Tg(Chx10-EGFP/cre, ALPP)2Clc/J (called Chx10-cre mice for 
the remainder of this manuscript), Vhltm1Jae/Vhltm1Jae (called Vhlflox/flox mice for the 
remainder of this manuscript) and C57BL/6J mice were obtained from the Jackson 
Laboratory (Bar Harbor, ME, USA). Tg(Chx10-EGFP/cre, ALPP)2Clc/J and Vhltm1Jae/
Vhltm1Jae mice were crossed for multiple generations to make homozygous Tg(Chx10-
EGFP/cre, ALPP)2Clc/J × Vhltm1Jae/Vhltm1Jae mice, named Chx10-cre; Vhlflox/flox mice for 
the remainder of this manuscript.
PCR analysis
Genotyping was performed with complementary DNA isolated from either the tails or 
retinas. The primers, reaction/components and cycling conditions were taken from the 
Jackson Laboratory website (www.jax.org).
Quantitative real-time PCR analysis
Retinal extracts from C57BL/6J and Chx10-cre; Vhlflox/flox transgenic mice were collected 
at postnatal days (P) 2, 5, 7 and 21. RNA was collect using the RNeasy Mini kit (Qiagen, 
Germantown, MD, USA). Complementary DNA was made using the SuperScript III First 
Strand Synthesis SuperMix for qRT-PCR (Invitrogen, Grand Island, NY, USA). Samples 
were run on a 96-well plate using TaqMan Real-time PCR assays on the Applied Biosystems 
ABI7500 Real-time PCR machine (Applied Biosystems, Grand Island, NY, USA). Cycling 
threshold (Ct) values were used to determine the delta Ct and delta–delta Ct values for 
analysis as previously published.17,18
Wert et al. Page 3
Signal Transduct Target Ther. Author manuscript; available in PMC 2016 May 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Immunoblot analysis
Retinal extracts from P10 mice were normalized for protein content (40 μg) and were 
incubated with the following primary antibodies: anti-von Hippel Lindau N-terminal (1:100; 
Abcam, Cambridge, MA, USA), anti-HIF-1 alpha (1:1000; Novus Biologicals, Littleton, 
CO, USA) and rabbit anti-cytoskeletal actin (1:300; Bethyl Laboratories, Inc., Montgomery, 
TX, USA) at 4 °C overnight. Membranes were probed with goat anti-rabbit IgG-HRP 
(1:2000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA). All further methods are 
previously described.19
Frozen sections and whole mounts
Mice were killed according to the established Institutional Animal Care and Use Committee 
guidelines. Eyes were enucleated, incubated in 2% paraformaldehyde at room temperature 
for 1 h, and then washed twice with phosphate-buffered saline (PBS; Invitrogen, Carlsbad, 
CA, USA). For retinal sections, eyes were equilibrated in sucrose, embedded in optimum 
cutting temperature compound (Sakura Fineteck, Torrance, CA, USA) and frozen. Frozen 
eyes were sectioned at 10 μm. For retinal whole mounts, the optic nerve, cornea and lens 
were removed and the entire eyecup was flattened by making four radial cuts that extended 
out from the optic nerve.
Immunostaining
Sections were permeabilized with 0.1% Triton-X100 (Fisher Scientific, Fair Lawn, NJ, 
USA) in PBS (PBS-T) and blocked in 5% goat serum. Sections were stained with one of the 
following primary antibodies: CD31 (1:20; BD Biosciences, San Jose, CA, USA), VEGFA 
(1:1000; Abcam), HIF1α (1:500; Novus Biologicals) and VHL (1:100; Santa Cruz 
Biotechnology). Secondary antibodies were Cy3-conjugated donkey anti-Rat (Jackson 
ImmunoResearch Laboratories Inc., Bar Harbor, ME, USA), Alexa Fluor 488 donkey anti-
rat (Invitrogen), Alexa Fluor 488 and Alexa Fluor 555 goat anti-rabbit (Invitrogen), and 
Alexa Fluor 555 goat anti-mouse (Invitrogen) at 1:500. Sections were imaged using a Leica 
DM 5000B microscope at × 2.5 and × 40 magnification (Leica Microsystems Inc., Wetzlar, 
Germany).
Electroretinograms
Mice were dark-adapted overnight, manipulations were conducted under dim red light 
illumination and recordings were made using Espion ERG Diagnosys equipment (Diagnosys 
LLL, Littleton, MA, USA). Adult C57BL/6J control mice were tested at the beginning of 
each session to ensure equal readouts from the electrodes for both eyes before testing the 
transgenic experimental mice. Both eyes were recorded simultaneously. A total of 40–60 
responses were averaged for each trial. All further detail on the electroretinogram (ERG) 
method has been described previously.19,20 Unpaired t-tests between C57BL6/J controls and 
transgenic mice were used to determine statistical significance for the a- and b-wave 
maximal amplitudes at 1 and 2 months of age.
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Perfusions
Confocal images were collected from mice that had been intraperitoneally injected with a 
lethal dose of anesthesia (1 ml ketamine 100 mg ml−1 (Ketaset III, Fort Dodge, IA, USA) 
and 0.1 ml xylazine 100 mg ml−1 (Lloyd Laboratories, Shenandoah, IA, USA) in 8.9 ml 
PBS). Incisions opened the chest cavity and exposed the heart. A vacutainer blood collection 
needle was inserted into the left ventricle of the heart, and the right atrium was clipped with 
Vannas scissors. Saline (2.5 cc) was delivered through the blood stream via the heart, 
followed by fluorescein or rhodamine dextran dye to label the blood vasculature. Eyes were 
enucleated and retinal whole mounts were then processed as above without further 
immunostaining.
Histology
Mice were killed according to institutional guidelines. Each eye was rapidly removed, 
punctured at the 12 o’clock position along the limbus and placed in a separate solution of 
2% paraformaldehyde, 2.5% glutaraldehyde, 0.1 M sodium phosphate buffer in PBS 
(Electron Microscopy Sciences, Hatfield, PA, USA) for 1–2 days. After fixation, the eyes 
were washed with saline and the 12 o’clock limbal puncture was used to orient the right and 
left eyes (which were kept separate) so that the posterior segment containing the retina could 
be sectioned along the vertical meridian. A rectangular piece containing the entire retina 
from superior to inferior ora serrata, including the optic nerve, was prepared for postfixing 
via osmic acid, dehydration and upon embedding. A corner was cut from the superior ora to 
mark the upper retinal half of the segment for orientation. Sectioning proceeded along the 
long axis of the segment so that each section contained upper and lower retina as well as 
posterior pole. Semi-serial sections were stained with either hematoxylin and eosin or 
toluidine blue, mounted and examined by light microscopy.
Fundoscopy and iris angiography
In vivo microscopy and digital imaging were performed as described previously,21 using an 
M2Bio fluorescence stereo microscope Stemi SV1 (Carl Zeiss, Oberkochen, Germany). For 
in vivo observation, mice were anesthetized with 3% isoflurane in oxygen. The eye was 
lightly proptosed and Viscotears (Novartis, Basel, Switzerland) was applied to the cornea 
after which a circular 7.5-mm sapphire window (Edmund Optics, Barrington, NJ, USA) was 
placed over the cornea. Fundus images were collected with a digital camera through a × 1.6 
objective and a zoom at × 2 or × 4 magnification (Coolsnap ES, Roper, TX, USA). Image 
resolution was ~ 1.0 and 2.0 μm per pixel with the × 4 and × 2 magnification, respectively. 
Fluorescent images were acquired under identical conditions. The intensity of excitation 
light at 430 nm was monitored with a power meter (Optical Power Meter Model 840, 
Newport Corp., Irvine, CA, USA) to ensure reproducibility. Serial fluorescein angiography 
was used with argon blue illumination and a fluorescein barrier filter. One bolus containing 
0.2 ml fluorescein (100 mg ml−1) was injected into the tail vein.
Retinal angiography and autofluorescence imaging
Angiography and AF imaging were obtained with the Spectralis optical coherence 
tomography scanning laser confocal ophthalmoscope (OCT-SLO Spectralis 2; Heidelberg 
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Engineering, Heidelberg, Germany) as previously described.22,23 In brief, pupils were 
dilated using topical 2.5% phenylephrine hydrochloride and 1% tropicamide (Akorn Inc., 
Lakeforest, IL). Mice were anesthetized by intraperitoneal injection of ketamine/xylazine as 
described above. During the procedure, body temperature was maintained at 37 °C using a 
heating pad. A measure of 0.05 ml of 10% AK-Fluor (100 mg ml−1, Akorn Inc.) was 
injected intraperitoneally. Imaging was obtained at 488-nm absorption and 495-nm emission 
using a 55° lens. Images of the central retina were taken, with the optic nerve located in the 
center of the image.
Statistics
All statistics used the two-tailed unpaired t-test and error bars display the mean value ± 
s.d.’s. P<0.05 was considered to be statistically significant.
RESULTS
Vitreous samples from DR patients contain elevated levels of HIF1α
Human DR patient retinal tissue has previously been shown to upregulate both 
erythropoietin (EPO) and VEGF, suggesting a potential role of HIF1α in the progression of 
DR.24 Furthermore, HIFs have recently been linked to a wide range of diseases, such as 
inflammatory diseases, ischemic disorders, metabolic syndrome and type 2 diabetes.15,25 To 
determine whether HIF1α was active in human PDR, we collected vitreous from patients 
with DR, as it has been shown that the retina releases proteins into the vitreous.26,27 During 
vitrectomy surgery, we collected samples from patients with active PDR (three patients) and 
two control sets of patients: those without DR (four patients) and patients in which prior 
panretinal laser photocoagulation (PRP) was used to ablate the ischemic retina and inhibit 
neovascularization (three patients; Figure 1).22 Untreated PDR patients showed early signs 
of neovascularization, exudates and hemorrhages on both fundus (top) and angiography 
images (bottom; Figure 1b). For PRP-treated DR, patients showed signs of laser scarring 
that was visible in after-surgery images of the fundus (top) and angiography images (bottom; 
Figure 1c), but no neovascularization.
Enzyme-linked immunosorbent assays revealed low levels of HIF1α in the vitreous from 
control samples (Figure 1d). In PDR patients who had not received any PRP laser therapy, 
there was significantly elevated levels of HIF1α (P<0.005). In PDR patients who had 
received PRP laser therapy with successful regression of neovascularization, the levels 
returned to baseline. These results were intriguing, as HIF1α is a ubiquitous transcription 
factor that drives expression of genes such as EPO, VEGF, CXCR12 and nitric oxide 
synthase (all of which cause neovascularization) and regulates adaptive responses to hypoxia 
(that is, glycolysis, erythropoiesis, angiogenesis and vascular remodeling).23,28,29
Establishment of a preclinical model of PDR
As there was elevated HIF1α expression in human PDR eyes, overexpression of HIF1α 
specifically in the mouse neuroretina might offer a preclinical, DR model. To elevate retinal 
HIF1α, we chose its natural upstream regulator, VHL. Under normoxic conditions, VHL 
marks HIF1α for ubiquitin-mediated degradation.30,31 We ablated VHL specifically in 
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retinal neurons (global VHL expression causes embryonic lethality)31,32 and expected this 
would constitutively elevate HIF1α levels in the retina.
Mice deficient for retinal VHL (VHL knockouts) were derived from Vhlflox/flox mice 
(Jackson Laboratory) that harbor Vhl alleles flanked by loxP sites. These mice were crossed 
with Chx10-cre mice, which express cre specifically in the fetal neuroblasts, photoreceptors 
and adult bipolar cells of the neuroretina. PCR analysis verified retinal Vhl knockout in the 
resultant offspring (Figures 2a and b).
HIF1α protein levels are elevated in the Chx10-cre; Vhlflox/flox murine model
To assess whether the neuroretina knockout of the Vhl gene caused protein changes in mice 
that phenocopied human DR patients, protein levels in the retina were analyzed in 
Vhlflox/flox cre-negative mice and Chx10-cre; Vhlflox/flox mutant mice at P10 (Figure 2c). 
Compared with the control, VHL was significantly reduced in the mutant mouse, although a 
residual level of VHL was still detectable (Figure 2c). More importantly, as in human DR 
patients (Figure 1), mutant mice greatly upregulated HIF1α expression in the retina (Figures 
2c and 3a–f), supporting the notion that the VHL knockout mouse offers a preclinical model 
for DR and ischemic retinopathies. Platelet endothelial cell adhesion molecule (PECAM), 
marking the blood vasculature, is found infiltrating the retinal cell layers, which are highly 
disorganized, in the transgenic mice in comparison with the control mice (Figures 3a–f). 
Despite these changes, VEGF protein, a downstream target of HIF1α transcriptional 
activation, remained unchanged in the mutant relative to control mice (Figures 3g–l).
Photoreceptor elevation of HIF1α leads to upregulation of the downstream transcriptional 
targets, EPO and Vegf, in the Chx10-cre; Vhlflox/flox mutant mouse retinas after 1 week of 
age
As VEGF is a secreted protein and the changes in VEGF protein levels may not be 
detectable within the retina, we performed quantitative PCR to test for EPO and Vegf 
messenger RNA expression (Figure 4). Retinas were extracted from mice during early and 
late stages of the disease phenotype. At 1 week of age (P7), when neovascularization has 
become visible in the mutant mouse eyes, EPO expression was beginning to be upregulated 
in the mutant mouse retinas in comparison with cre-negative control retinas (Figure 4a). At 1 
week of age, there is also a significant upregulation of Vegf in the retinas of the mutant mice 
in comparison with the cre-negative control retinas (Figure 4b). At 1 month of age (P28), 
when the PDR phenotype is severe and some retinal detachment can be found in the mutant 
murine model, EPO remained highly upregulated in the Chx10-cre; Vhlflox/flox mutant 
mouse retinas in comparison with a control Vhlflox/flox cre-negative mouse retina; however, 
Vegf levels were comparable between the control and mutant mice, verifying the protein 
staining results (Figures 4a and b). As expected, Vhl messenger RNA levels were reduced in 
the Chx10-cre; Vhlflox/flox mutant mouse retinas compared with the Vhlflox/flox cre-negative 
mouse retinas (Figure 4c).
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The Chx10-cre; Vhlflox/flox murine model exhibits anterior segment ischemia, vitreous 
hemorrhage and tractional retinal detachment similar to human patients with late-stage 
PDR
Within the retina of human DR patients, ischemia, capillary dropout and abnormal 
angiogenesis cause neovascularization and hemorrhaging. To test whether the Chx10-cre; 
Vhlflox/flox mutant mice developed similar abnormalities, histological sections were 
examined from Chx10-cre; Vhlflox/flox mice at 1 month of age (Figure 5). Similar to human 
DR patients, these mice showed neovascularization throughout the eye (Figures 5a, b and d), 
retinal degeneration with disorganization of the retinal cell layers (Figure 5c), and retinal 
membranes and traction (Figures 5c and d). Each of these histological findings suggests that 
these mice exhibit key features of PDR and model advanced stages of the human disease.
The Chx10-cre; Vhlflox/flox murine model exhibits a loss of visual function
Histological analysis of the Chx10-cre; Vhlflox/flox mutant mice at 1 month of age displayed 
abnormal retinal organization (Figure 5). Therefore, we examined visual function using 
ERGs at both 1 and 2 months of age (Figure 6). Under maximum rod–cone scotopic ERG 
settings at 1 month of age, the mutant mouse (gray) had a low b:a wave ratio in comparison 
with that of the control mouse (black; Figure 6a). A cohort of mice (n>5) was then analyzed 
by ERG at both 1 and 2 months of age. The a-wave of the maximum rod–cone scotopic ERG 
response was significantly reduced at 1 month of age (−96.3 ± 30.2 μV in the control mice 
and − 19.0 ± 22.7 μV in the mutant mice; P<0.0001) and the a-wave amplitude remained 
significantly reduced at 2 months of age (−159.4 ± 52.8 μV in the control mice and − 22.3 
± 40.5 μV; P = 0.0011; Figure 6b). In addition, the b-wave amplitude of the maximum rod–
cone scotopic ERG response was also significantly reduced at both 1 month of age (239.8 
± 59.1 μV in the control mice and 28.1 ± 21.8 μV in the mutant mice; P<0.0001) and 2 
months of age (394.6 ± 105.2 μV in the control mice and 47.5 ± 29.5 μV in the mutant mice; 
P<0.0001; Figure 6c). Overall, visual function was attenuated in the Chx10-cre; Vhlflox/flox 
mutant mice in comparison with wild-type controls, likely due to the retinal ischemia in 
these mice.
The Chx10-cre; Vhlflox/flox murine model exhibits vasculature defects found in human PDR 
patients
In addition, we evaluated the irises of the Chx10-cre; Vhlflox/flox mutant mice at P10. 
Angiography revealed that they indeed developed anterior segment ischemia (Figures 7a–d), 
and in images of time-lapse angiograms (Figures 7e–h), magnification revealed leaking 
fluorescein dye indicative of iris rubeosis (Figures 7f and h). In addition, the anterior surface 
of their irises developed a fibrovascular membrane (Figures 7a–d). These findings are 
consistent with the early development of late-stage PDR in the Chx10-cre; Vhlflox/flox 
mutant mouse model.
The neovascularization on the surface of the iris and nearby structures in the Chx10-cre; 
Vhlflox/flox mice can elevate intraocular pressure and further damage the optic nerve, as with 
human neovascular glaucoma. Accordingly, fundus photographs of the mutant mice revealed 
phenotypes associated with neovascular glaucoma, retinal ischemia and PDR at 3 months of 
age (Figures 7i–k). Vitreous hemorrhage was clearly visible in ~ 60% of the mutant mice 
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(Figure 7i), as was cataract formation (Figure 7j) anterior synechia (Figure 7k) and 
neovascular glaucoma (Figures 7j and k). In addition, retinal vessels in the mutant mice 
leaked fluorescein dye and demonstrated capillary dropout, suggesting that their condition is 
similar to human PDR (Figure 7n). In contrast, for both the control C57BL/6J mouse (Figure 
7l) and a Chx10-cre; Vhlflox/+ heterozygous mouse (Figure 7m), retinal angiograms showed 
normal retinal vasculature and no detectable phenotype.
To confirm the angiography results, retinas were flat mounted and stained with PECAM 
(CD31), a vascular endothelial cell marker. In addition, because mutant mouse retinas were 
susceptible to damage during the staining procedure before the eyes were isolated for 
analysis, mice were perfused with a rhodamine dextran dye to delineate the retinal vessels 
(Figure 8). Retinal vasculature of C57BL/6J control mice (Figure 8a), the Vhlflox/flox mouse 
model without cre expression (Figure 8b) and Chx10-cre; Vhlflox/+ heterozygous mice 
(Figure 8c) all showed normal retinal blood vessels at >3 months of age. In contrast, by P8, 
the Chx10-cre; Vhlflox/flox mutant mice had developed severe retinal blood vessel 
abnormalities (Figure 8d). In homozygous mutant mice, the primary vascular plexus 
developed normally until P8; from P8 on, their retinas were affected by capillary dropout, as 
indicated by non-perfused hypo-fluorescent patches (Figure 8d; yellow arrows). In addition, 
neovascularization was observed on the optic disc and a neovascular network surrounded the 
optic nerve (neovascularization of disc; Figure 8d; blue arrow), forming a membrane made 
of new, fragile blood vessels. In human PDR patients, a similar, fragile neovascular network 
develops and hemorrhages into the vitreous. Neovascular membranes are responsible for the 
tractional retinal detachments in humans with PDR.
In contrast to the oxygen-induced retinopathy mouse models used for ischemic 
retinopathies, there was no revascularization of the retina in our mutant mouse. Indeed, the 
retinal vasculature abnormalities persisted through at least P150 (data not shown). Closer 
examination of the retinal capillaries showed that compared with 2-month-old heterozygous 
Chx10-cre; Vhlflox/+ mice (Figure 8e), the homozygous mutant Chx10-cre; Vhlflox/flox mice 
were already losing capillaries at P5 (Figure 8f; yellow arrows) and the perfusion dye leaked 
from the sites of abnormal and hemorrhaging blood vessels that extended to the peripheral 
retina (Figure 8f; blue asterisks).
DISCUSSION
The late-stage clinical phenotype of DR, in particular retinal edema and neovascularization, 
leads to the adverse effects on vision.33 However, animal models for DR are mainly limited 
to mild retinal disease in comparison with human DR patients. Here we examined human 
PDR patients with and without treatment and determined that elevated HIF1α was found in 
patients with PDR. We then developed an improved preclinical animal model for human 
PDR. Elevated HIF1α from the photoreceptor cells allows for irreversible vascular 
abnormalities in mice deficient in VHL in the neural retina. In our model, the phenotype 
begins and progresses similar to the clinical presentation of human PDR during the 
development and growth of the mouse. This new model provides greater clinical relevance 
when testing therapeutic treatments for PDR and will be useful for developing novel 
therapies for other ischemic retinal neovascular diseases, including branch retinal vein 
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occlusions, sickle cell retinopathy and inherited neovascular inflammatory 
vitreoretinopathy.17
Recently, murine models were developed that inactivate VHL within the eye, which may 
lead to elevation of HIF1α as we have found in our murine model system.34–37 Although 
global knockout of VHL causes embryonic lethality, these conditional knockout models 
targeted specific cell types of the eye and were viable. An astrocyte-specific knockout of 
VHL displayed accelerated primary hyaloidal vascular regression and massive secondary 
outgrowth of hyaloid vessels.34 A retinal pigment epithelial-specific knockout of VHL 
developed abnormal retinal pigment epithelials, irises, ocular growth and vasculature in the 
anterior chamber.35 VHL knockout in the distal retina and iris (via a Pax6 alpha::cre driver) 
caused abnormal vasculature and retinal cell death.36 VEGF, VHL and HIF1α conditional 
deletions in the horizontal and amacrine cells reduced blood vessel branching points and 
lead to a loss of visual function and photoreceptor cells.37 None of these models, however, 
developed phenotypes that mimic advanced human PDR nor did their vascular phenotype 
progress from non-PDR to PDR; nevertheless, each displayed abnormal retinal vasculature 
consistent with the idea that the VHL/HIF1 pathway has a role in DR development and 
inflammatory/ischemic diseases. These findings support the concept that photoreceptor 
ischemia is the driving force behind PDR, and specific metabolic modulation of 
photoreceptors may be a therapeutic strategy for the treatment of DR.
Recent studies have concluded that photoreceptors have a role in the progression of DR 
before retinal neovascularization, but the exact role of photoreceptors and neurodegeneration 
are still unknown.38 Understanding the pathogenesis of retinal neovascularization in DR 
patients, including neuronal dysfunction that leads to neurodegeneration and vision loss, is 
highly important for the prevention of vision loss in patients with diabetes. In our model, 
Vhl was absent and Hif1α was elevated in the inner retina during early development. Using 
various in vivo and other experimental methods, such as angiography and histological 
analysis, we determined that the Chx10-cre; Vhlflox/flox mutants develop retinal disease in a 
similar sequence as humans that develop retinal ischemia and PDR (Figures 2–8). Elevation 
of EPO, VEGF and vitreous hemorrhage began on approximately P4; and by 3 weeks of age, 
these mice typically progressed to tractional retinal detachment. This was the direct 
consequence of severe capillary dropout, the formation of ischemic retinal areas, and 
fibrovascular membranes, all of which are promoted by HIF1α activity. This preclinical 
model of PDR can be used to investigate the mechanisms underlying the severe disease 
phenotypes as it is an early-onset model system with no reversal of the phenotype. For 
instance, the mechanisms of cell death in DR are still mostly unknown, with some studies 
showing apoptosis, whereas others suggest various different pathways.39–42 In addition, as 
retinopathy in our new mutant mice progresses in a matter of weeks, these mice offer an 
excellent model for rapid testing of therapeutic agents for this group of incapacitating 
disorders and different time points of disease progression could be specifically targeted.6,43
In summary, we developed a novel murine model of neovascularization, hemorrhage and 
retinal ischemia characteristic of human patients with PDR. This mouse model can be used 
to dissect the mechanisms leading to PDR, and can be used to develop treatments for PDR, 
as it is the first murine model that has a neovascular and ischemic retinal phenotype that 
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does not reverse over time. Furthermore, our newly developed murine model should 
contribute to knowledge and discovery of similar retinal neovascular diseases, including the 
retinopathy of prematurity, age-related macular degeneration and tumorigenesis, as well as 
the study of normal retinal vasculogenesis and the understanding of the HIF signaling 
pathways to treat a wide range of inflammatory and ischemic diseases.
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Figure 1. 
Increased HIF1α protein levels in human patients with untreated proliferative diabetic 
retinopathy (PDR). Fundus (top) and fluorescein angiographic images (bottom) of the 
retinae of patients without PDR (a), PDR patients who were untreated (b) and patients with 
PDR who underwent prior panretinal photocoagulation (PRP) laser treatment (c). Enzyme-
linked immunosorbent assays on vitreous samples taken from each patient group determined 
that HIF1α protein levels were similar in the vitreous of both control patients and treated 
PDR patients, but significantly elevated (P<0.005) in PDR patients who were not treated at 
the time of analysis (d). N = 4 patients without PDR, 3 patients with untreated PDR and 3 
patients with PDR who underwent PRP laser treatment. Error bars represent s.d.’s.
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Figure 2. 
Increased HIF1α but decreased VHL levels in the Chx10-cre; Vhlflox/flox mutant mice. A 
schematic of the Vhl gene, displaying exon 1 and the loxP sites of the Vhlflox/flox mice 
shows the location of the primers used to detect cre-mediated recombination after 
crossbreeding with Chx10-cre mice (a). Primers P2 and P3 detect the loxP sites in retinal 
DNA samples. Primers P1 and P3 detect cre-mediated recombination. PCR analysis of 
retinal samples after cross-breeding of the Vhlflox/flox mice with the Chx10-cre mice (b). A 
290-bp band is visible for wild-type alleles (sample 1), whereas a 460-bp band is visible for 
the 2-lox allele (samples 4 and 5), and a double band at both sites is detected in 
heterozygous allele mice (samples 2 and 3), which harbor one wild-type allele and one with 
2-lox sites. Cre expression was found in samples 3 and 5, both of which displayed cre-
mediated recombination to produce a 1-lox mutant allele (signal at 290 bp). Immunoblot 
analysis of HIF1-alpha and VHL protein levels in Vhlflox/flox cre-negative control mice (lane 
1) and Chx10-cre; Vhlflox/flox mutant mice (lane 2) at postnatal day 10 (c). β-Actin was used 
as a loading control.
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Figure 3. 
Cre-mediated recombination causes increased HIF1α. Protein levels were analyzed by 
immunostaining frozen retinal sections for Vhlflox/flox cre-negative mice and Chx10-cre; 
Vhlflox/flox mutant mice at 1 month of age. Both PECAM (green; a) and HIF1α (red; b) 
protein levels were present in Vhlflox/flox cre-negative mice, but PECAM (d) and HIF1α (e) 
protein levels were only elevated after cre-mediated excision of the Vhl gene. Merged 
images for the Vhlflox/flox cre-negative mice (c) and Chx10-cre; Vhlflox/flox mutant mice (f) 
show combined PECAM (green) and HIF1α (red) protein levels in the retina. Vascular 
endothelial growth factor (VEGF; green) was similar between the Vhlflox/flox cre-negative 
mice (g) and Chx10-cre; Vhlflox/flox mutant mice (j), whereas HIF1α (red) was increased as 
expected in the mutant mice (k) compared with the cre-negative mice (h). Merged images 
for the cre-negative mice (i) and mutant mice (l) show VEGFA and HIF1α overlayed on the 
same figure. Both the sections for PECAM and HIF1α, and those for VEGFA and HIF1α 
were taken at the same exposure. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, 
outer nuclear layer. Scale bar, 600 μm.
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Figure 4. 
Upregulation of erythropoietin and vascular endothelial growth factor in the PDR murine 
model. Quantitative PCR of erythropoietin (EPO) showed an upregulation of EPO in the 
Chx10-cre; Vhlflox/flox mutant mouse retinas compared with Vhlflox/flox control mouse 
retinas at 1 week of age, during the onset of neovascularization and the PDR disease 
phenotype (a). The upregulation of EPO continued through 1 month of age, when 
hemorrhaging and retinal detachment can be found in this mouse model (a). Vascular 
endothelial growth factor (Vegf) was highly upregulated in the Chx10-cre; Vhlflox/flox mouse 
retinas at the onset of disease (1 week of age), but became comparable to the control 
Vhlflox/flox mouse retinas by 1 month of age (b). von Hippel Lindau tumor suppressor 
protein (Vhl) was reduced in the mutant Chx10-cre; Vhlflox/flox mouse retinas compared 
with the control Vhlflox/flox mouse retinas at all time points analyzed as would be expected 
with the expression of cre (c). N ⩾ 4 for each group at each time point. Error bars show 
s.d.’s. *P<0.01.
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Figure 5. 
Neovascularization and retinal degeneration in the PDR murine model. Hematoxylin and 
eosin (H&E)-stained pupil optic nerve sections from eight Chx10-cre; Vhlflox/flox mice. At 1 
month of age, the mice displayed signs of iris neovascularization (arrow) and protein 
extravasation in the anterior chamber (arrowhead), a sign of vascular leakage (a). There was 
optic disc neovascularization (arrow) and fibrosis in the vitreous (b), retinal photoreceptor 
degeneration (arrow) and vitreoretinal membranes (arrowhead) (c). Tractional vitreoretinal 
membranes (arrowhead) and vitreous neovascularization (arrow) were observed (d). N = 12 
eyes. All mice displayed neovascular and retinal degenerative phenotypes.
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Figure 6. 
Loss of visual function in the PDR murine model. A representative electroretinogram (ERG) 
trace at 1 month of age for maximum scotopic rod–cone mixed visual function displayed a 
severely attenuated visual response in the Chx10-cre; Vhlflox/flox mutant mice (gray) 
compared with C57BL/6J wild-type control mice (black; a). Quantification of the ERG 
maximum scotopic a-wave amplitude (labeled in a) for a cohort of mice displayed a 
significant loss of a-wave amplitude in the Chx10-cre; Vhlflox/flox mice compared with 
C57BL6/J controls at both 1 month of age (P<0.0001) and 2 months of age (P<0.0011; b). 
Similarly, there was a significant loss of the b-wave visual function (labeled in a) for the 
Chx10-cre; Vhlflox/flox mice at both 1 month of age (P<0.0001) and 2 months of age 
(P<0.0001; c). N>5 mice per group for each time point analyzed. Error bars show s.d.’s.
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Figure 7. 
Neovascularization and leakage in the Chx10-cre; Vhlflox/flox mutant mouse mimics the 
human proliferative DR (PDR) phenotype. Time-lapse images from iris angiography at 
postnatal day 10 (P10) reveals anterior segment ischemia, rubeosis and iris synechaie (a–e, 
g). Enhanced images of fluorescein leakage in the iris during time-lapse angiography (f, h). t 
= 10 s post-fluorescein dye injection. Fundus photographs of mutant mice at 3 months of 
age, showing visible vitreous hemorrhage (i), cataract (j) and signs of anterior segment 
ischemia (k). Fluorescein angiography in mice older than 1 month of age, for a wild-type 
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C57BL/6J mouse (l) and a Chx10-cre; Vhlflox/+ heterozygote (m), uncovered no fluorescein 
leakage or detectable abnormalities of the retinal vasculature. In contrast, at P19, 
angiography of the Chx10-cre; Vhlflox/flox mutant mouse detected leaking fluorescein dye 
and capillary dropout, characteristic of PDR in humans (n). N ⩾ 4 mice, phenotype was 
visible in all mice examined.
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Figure 8. 
Retinal whole-mount analysis shows Chx10-cre; Vhlflox/flox mutant mice develop a PDR 
phenotype. Retinal whole mounts were analyzed at >3 months of age for a C57BL/6J control 
mouse (a), a Vhlflox/flox mouse model without cre expression (b) and a Chx10-cre; Vhlflox/+ 
heterozygous mouse model (c). PECAM (CD31) staining revealed that the three controls 
had developed a normal capillary bed. In contrast, by postnatal day 8 (P8), the homozygous 
Chx10-cre; Vhlflox/flox mutant mice had developed severe retinal blood vessel abnormalities 
(d). Rhodamine dextran perfusions displayed normal capillaries at 2 months of age in 
Chx10-cre; Vhlflox/+ heterozygous mice (e), whereas capillary dropout and dye leakage 
denoting neovascularization is visible by P5 in a homozygous mutant (f). Blue asterisk, 
neovascularization; yellow arrow, capillary dropout; blue arrow, neovascularization of the 
optic disc. N ⩾ 5 mice, with all mice showing represented retinal phenotypes. Scale bar, 200 
μm.
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